制药公司选择在澳大利亚制造，刺激国内经济

澳大利亚生物技术公司Sasmar今天宣布将其计划生育线的所有制造业转移到澳大利亚市场。

Sasmar, an Australian biotechnology company, announced today that is has moved all manufacturing of its family planning lines to the Australian market. Sasmar CEO John-Michael Mancini said, “With many Australians concerned by the slump in the economy, and worried about their jobs, their mortgages, their bills and taking care of their children, we have moved manufacturing to add value locally. We are pleased about the new jobs this move has created in the Australian market.” Sasmar, an Australian biotechnology company, announced today that is has moved all manufacturing of its family planning lines to the Australian market. Sasmar CEO John-Michael Mancini said, “With many Australians concerned by the slump in the economy, and worried about their jobs, their mortgages, their bills and taking care of their children, we have moved manufacturing to add value locally. We are pleased about the new jobs this move has created in the Australian market.” 

 
Martin White, partner of accounting firm Jacoby Cameron & Co said, “Australia’s $42 billion recession-fighting stimulus package will see more than seven million Australians receiving $900 cash handouts from today. To inject this money into the Australian economy we must look at buying Australian made products." 
 
Mr Mancini said that consumers should be checking labels to see where products are made. "Australian made products are usually of better quality and the money stays here," he said.
 
Labeling that includes ‘Made in Australia’ is injecting money into the national economy.
 
“Amongst our social circles someone has lost their job, people are questioning if they will be next," said mother of two Jennifer Johnstone of St Ives. "it is fantastic to see companies thinking about how their decisions affect the average Australian."
 
分析这篇文章
​ ​ ​
存档
澳大利亚制药公司打破了世界各地的妈妈的构想障碍
澳大利亚制药公司Sasmar在美国受尊敬的大学医院的生育专家三年的发展后发布了其概念产品。
​